Tag: NANS 2023

SCS therapies can play a role in cancer-related pain treatment despite...

Spinal cord stimulation (SCS) therapies targeting the dorsal column “may be considered” within the multimodal treatment plans typically required by cancer patients, but it...

Boston Scientific announces three-month data from SOLIS trial at NANS

Combination spinal cord stimulation (SCS) therapy with Boston Scientific’s WaveWriter system has demonstrated superior outcomes to conventional medical management (CMM) in chronic pain patients...

Abbott presents new data on streamlining patient-reported measures, BurstDR and more...

Abbott presented new data in more than 30 presentations and posters at the North American Neuromodulation Society (NANS) annual meeting (12–15 January 2023, Las...

Saluda Medical announces presentation of 36-month EVOKE trial data at NANS...

Saluda Medical has announced that late-breaking data from the "landmark" EVOKE clinical trial was presented at the recent North American Neuromodulation Society (NANS) annual...

Saluda Medical initiates US commercialisation of the Evoke spinal cord stimulation...

Saluda Medical has announced plans for a limited commercial release of its Evoke spinal cord stimulation (SCS) system in the USA, with a full commercial...